Execs On The Move: January 19–23, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - January 29, 2026

Takeda Touts Trinity Of Rusfertide, Oveporexton, Zasocitinib In Growth Strategy
Vyvanse weighed on sales growth in the third quarter amid generic competition, but the losses are declining and the Japanese drugmaker is looking to new launches this year.
Scrip - January 29, 2026

Asia Deal Watch: Kanghua Will Move Into Vaccines By Purchasing Chinese Peer NanoRibo
Plus deals involving Insilico/Qilu, Insilico/Hygtia, AstraZeneca/AbelZeta, Alteogen/Tesaro, Ellipses/Innolake and more.
Scrip - January 29, 2026

As Novo Nordisk Doubles Down In Obesity And Diabetes, What Exactly Is It Looking For?
Scrip spoke with Novo’s SVPs for global research and global business development, Jacob Petersen and Tamara Darsow, about dealmaking and R&D priorities after the company streamlined to focus more intensely on obesity and diabetes.
Scrip - January 29, 2026

Repertoire Adds Lilly To Its Set Of ‘A-List’ Partners
Deal Snapshot: Following alliances with BMS, Genentech and Pfizer, Repertoire is partnering with Lilly to discover T-cell targeted autoimmune therapies. Deal continues a busy January for Lilly’s business development.
Scrip - January 29, 2026

Hey Doc, What’s That Sound? FDA Clearance Broadens Scope Of AI Heart Murmur Detection Platform
The US FDA has granted clearance to eMurmur, broadening the use of its AI-powered software platform. The innovative system identifies primary heart sounds to detect abnormal murmurs as they occur.
Medtech Insight - January 29, 2026

Illumina Pins 2026 Growth On Clinical Sequencing As Research Spending Stays Constrained
Illumina CEO Jacob Thaysen told JPMorgan analysts that clinical consumables, NovaSeq X adoption will anchor company’s near-term outlook amid muted academic demand.
Medtech Insight - January 29, 2026

Sanofi CEO Calls For Patience And Faith In Pipeline Ahead Of Dupixent Expiry
Paul Hudson has acknowledged the firm’s R&D setbacks but says they are par for the course when tackling science ‘that has never been done before.’
Scrip - January 29, 2026

Valbiotis Ready To Deliver On Big Ambitions
The France-based dietary supplements firm is targeting sales in excess of €25m next year.
HBW Insight - January 29, 2026

Roche CEO To Switzerland: You Need To Adapt To Pharma’s New World Order
CEO Thomas Schinecker is signalling that historic investment in Switzerland cannot be sustained unless the country makes its investment and pricing environment more pharma-friendly.
Scrip - January 29, 2026

When Brain-Computer Interfaces Fail, Human Trial Participants Have Few Options
In this final part of a three-part series, Medtech Insight spoke with a neuroethicist and the first person in a trial using a BCI implant for stimulating hand movement. This story explores ethical considerations that arise when projects can no longer support patients with implanted devices.
Medtech Insight - January 29, 2026

Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip. After extensive coverage of the Annual JPM Healthcare Conference in San Francisco, we also highlight some of the insightful and memorable quotes across the week.
Scrip - January 29, 2026

Alvotech Secures Immediate Launch Of Eylea Biosimilar In The UK And Canada
Alvotech has ticked off all of the remaining patent-related matters for its aflibercept biosimilar, with multiple market entries expected in 2026.
Generics Bulletin - January 29, 2026

Teva Positions For Long-Term Biosimilars Growth With 10 Launches From 2028
Teva says it has 10 additional biosimilars in development for launch from 2028 onwards, extending its portfolio beyond 2027 as it targets European growth and expands through partnerships.
Generics Bulletin - January 29, 2026

CalciMedica Shares Plunge After Discontinuing Phase II AKI Study
Attention now shifts to the company’s review of unblinded data and whether changes to patient enrolment could support further evaluation.
Scrip - January 29, 2026

From Vision to Reality: National Associations Map the Next Phase of Self?Care in 2026
Industry associations in the UK, Germany and Greece expect 2026 to be the year self?care policy is translated into day?to?day system change. They highlight opportunities in pharmacy, digital tools and regulatory reform, but warn that progress depends on political timing and regulatory agility.
HBW Insight - January 29, 2026

AstraZeneca Hails ‘Next Chapter’ In China With $15bn Investment Pledge
While China is already a key market for AstraZeneca, the UK-based firm has announced a $15bn investment commitment in the country to boost its capabilities in cell therapy and radioconjugates.
Scrip - January 29, 2026

Celltrion Reassures US Tariff Resilience After Trump Threatens Korean Trade Deal U-Turn
Even though the ink has long dried on the US-South Korea trade deal, new threats have prompted Celltrion to reiterate its “fundamental solution” to tariff concerns.
Generics Bulletin - January 29, 2026

With Fresh Funding, Tenpoint Looks To Launch Newly Approved Presbyopia Eye Drops
Tenpoint expects to launch its Yuvezzi eye drops in early Q2, where it will compete with other rivals such as LENZ’s Vizz, as well as more traditional options such as glasses and lenses.
Scrip - January 29, 2026

With Product Listing Off Menu, US FDA Supplement Programs’ Table Set For ‘Priority Deliverables’
Changing self-GRAS regulation, providing NDIN safety and identity guidance and modernizing supplement industry regulatory framework are on FDA’s “2026 priority deliverables,” but not requirement for public listing of all supplements available.
HBW Insight - January 29, 2026

New Medicare Negotiation List Spotlights Small Molecule Liability For Cancer Drugs
The process will pit breast cancer treatment competitors Kisqali and Verzenio against each other as CMS develops pricing offers.
Scrip - January 29, 2026